Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial
Open Access
- 30 July 2024
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 67 (10) , 2175-2187
Abstract
Aims/hypothesis: The apparent diffusion coefficient (ADC) derived from diffusion-weighted MRI (DWI-MRI) has been proposed as a measure of changes in kidney microstructure, including kidney fibrosis. In advanced kidney disease, the kidneys often become atrophic; however, in the initial phase of type 2 diabetes, there is an increase in renal size. Glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter 2 inhibitors both provide protection against progression of kidney disease in diabetes. However, the mechanisms are incompletely understood. To explore this, we examined the effects of semaglutide, empagliflozin and their combination on renal ADC and total kidney volume (TKV). Methods: This was a substudy of a randomised clinical trial on the effects of semaglutide and empagliflozin alone or in combination. Eighty patients with type 2 diabetes and high risk of CVD were randomised into four groups (n=20 in each) receiving either tablet placebo, empagliflozin, a combination of semaglutide and tablet placebo (herein referred to as the ‘semaglutide’ group), or the combination of semaglutide and empagliflozin (referred to as the ‘combination-therapy’ group). The semaglutide and the combination-therapy group had semaglutide treatment for 16 weeks and then had either tablet placebo or empagliflozin added to the treatment, respectively, for a further 16 weeks; the placebo and empagliflozin groups were treated with the respective monotherapy for 32 weeks. We analysed the effects of treatment on changes in ADC (cortical, medullary and the cortico–medullary difference [ΔADC; medullary ADC subtracted from cortical ADC]), as well as TKV measured by MRI. Results: Both semaglutide and empagliflozin decreased cortical ADC significantly compared with placebo (semaglutide: −0.20×10−3 mm2/s [95% CI −0.30, −0.10], p−3 mm2/s [95% CI −0.26, −0.04], p=0.01). No significant change was observed in the combination-therapy group (−0.05×10−3 mm2/s [95%CI −0.15, 0.05]; p=0.29 vs placebo). The changes in cortical ADC were not associated with changes in GFR, albuminuria, TKV or markers of inflammation. Further, there were no changes in medullary ADC in any of the groups compared with placebo. Only treatment with semaglutide changed ΔADC significantly from placebo, showing a decrease of −0.13×10−3 mm2/s (95% CI −0.22, −0.04; p=0.01). Compared with placebo, TKV decreased by −3% (95% CI −5%, −0.3%; p=0.04), −3% (95% CI −5%, −0.4%; p=0.02) and −5% (95% CI −8%, −2%; p1c. Conclusions/interpretation: In a population with type 2 diabetes and high risk of CVD, semaglutide and empagliflozin significantly reduced cortical ADC compared with placebo, indicating microstructural changes in the kidneys. These changes were not associated with changes in GFR, albuminuria or inflammation. Further, we found a decrease in TKV in all active treatment groups, which was possibly mediated by a reduction in hyperfiltration. Our findings suggest that DWI-MRI may serve as a promising tool for investigating the underlying mechanisms of medical interventions in individuals with type 2 diabetes but may reflect effects not related to fibrosis. Trial registration: European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) 2019-000781-38 GraphicalKeywords
Funding Information
- Lægeforeningen (2019-3780/41)
- Novo Nordisk Fonden (NNF170C0029064)
- Health Research Fund of Central Denmark Region (A3192)
- Sundhedsvidenskabelige Fakultet, Aarhus Universitet
- Aarhus Universitet
This publication has 47 references indexed in Scilit:
- The effects of semaglutide, empagliflozin and their combination on the kidney sodium signal from magnetic resonance imaging: A prespecified, secondary analysis from a randomized, clinical trialJournal of Diabetes and its Complications, 2024
- Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trialJournal of Diabetes and its Complications, 2023
- Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trialDiabetologia, 2023
- Sodium–glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanismsPharmacological Reports, 2022
- Effect of glucose regulation on renal parenchyma and sinus fat volume in patients with type 2 diabetesDiabetes & Metabolism, 2022
- Diffusion-magnetic resonance imaging predicts decline of kidney function in chronic kidney disease and in patients with a kidney allograftKidney International, 2022
- A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitorsCell Metabolism, 2021
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-artMolecular Metabolism, 2021
- Diffusion-weighted imaging in the assessment of renal function in patients with diabetes mellitus type 2Magnetic Resonance Materials in Physics, Biology and Medicine, 2020
- Multiparametric magnetic resonance imaging shows promising results to assess renal transplant dysfunction with fibrosisKidney International, 2020